GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Pretax Margin %

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Pretax Margin % : % (As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. CERo Therapeutics Holdings's Pre-Tax Income for the six months ended in Dec. 2022 was $-11.83 Mil. CERo Therapeutics Holdings's Revenue for the six months ended in Dec. 2022 was $0.00 Mil. Therefore, CERo Therapeutics Holdings's pretax margin for the quarter that ended in Dec. 2022 was %.

The historical rank and industry rank for CERo Therapeutics Holdings's Pretax Margin % or its related term are showing as below:


CERO's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.98
* Ranked among companies with meaningful Pretax Margin % only.

CERo Therapeutics Holdings Pretax Margin % Historical Data

The historical data trend for CERo Therapeutics Holdings's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Pretax Margin % Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Pretax Margin %
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Pretax Margin % - -

Competitive Comparison of CERo Therapeutics Holdings's Pretax Margin %

For the Biotechnology subindustry, CERo Therapeutics Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's Pretax Margin % falls into.



CERo Therapeutics Holdings Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

CERo Therapeutics Holdings's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-11.829/0
= %

CERo Therapeutics Holdings's Pretax Margin for the quarter that ended in Dec. 2022 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=-11.829/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CERo Therapeutics Holdings  (NAS:CERO) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


CERo Therapeutics Holdings Pretax Margin % Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines